Menu
Back to Journals » OncoTargets and Therapy » Volume 4
New developments in the treatment of metastatic gastric cancer: focus on trastuzumab
Authors Rose JS, Bekaii-Saab T
Published 24 March 2011 Volume 2011:4 Pages 21—26
DOI https://doi.org/10.2147/OTT.S10188
Review by Single anonymous peer review
Peer reviewer comments 2
Jeffrey S Rose, Tanios S Bekaii-Saab
Department of Internal Medicine, Division of Medical Oncology, The Ohio State University – Arthur James Cancer Hospital, Columbus, OH, USA
Abstract: Patients with metastatic gastric cancer have a poor outcome. The development of new combinations of chemotherapy has led to steady but only modest gains in overall survival with largest effects reported with two- and three-drug regimens. Trastuzumab, a fully humanized monoclonal antibody directed at the human epidermal growth factor receptor-2 (HER2), has been found to improve response rate and survival in patients with advanced gastric cancer. This update will review the role of HER2 and summarize therapeutic advances in the use of trastuzumab in advanced gastric cancer.
Keywords: gastric, gastroesophageal, adenocarcinoma, chemotherapy, trastuzumab
© 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.